Patients who took aspirin in either Age-Related Eye Disease Study did not show significant associations with progression to late age-related macular degeneration.
“We found no association of aspirin use with the progression to late AMD, either neovascular or geographic atrophy. We feel that patients who have AMD need not to avoid aspirin when medically indicated,” study co-author Emily Y. Chew, MD, told Healio/OSN.
Researchers analyzed the potential association between aspirin use and AMD progression in two prospective cohort studies within two controlled clinical trials. The analysis included AREDS participants aged 55 to 80 years and AREDS2 participants aged 50 to 85 years.
Of the 1,049 AREDS participants who took aspirin, 975 were matched by propensity score with 975 AREDS participants who did not take aspirin. Of the 1,950 matched participants, 454 progressed to late AMD, 345 progressed to geographic atrophy, and 278 progressed to neovascular AMD over a median follow-up of 10.1 years.
Of the 1,198 AREDS2 participants who took aspirin, 847 were matched by propensity score with 847 AREDS2 participants who did not take aspirin. Of the 1,694 matched participants, 643 progressed to late AMD, 402 progressed to geographic atrophy, and 341 progressed to neovascular AMD over a median follow-up of 5 years.
The researchers compared hazard ratios of progression in quintile 5, the highest propensity for aspirin use, vs. quintiles 2, 3 and 4, with quintile 1, the lowest propensity for aspirin use, used as the reference quintile. No significant associations with progression were found in quintile 2 through 5 for any of the three outcomes in either of the studies. – by Robert Linnehan
Disclosures: The authors report no relevant financial disclosures.